Novel Insights from Clinical Practice
Cholangiocarcinoma Complicating Secondary Sclerosing Cholangitis from Cryptosporidiosis in an Adult Patient with CD40 Ligand Deficiency: Case Report and Review of the LiteratureRahman M.a · Chapel H.b · Chapman R.W.a · Collier J.D.a
Departments of aHepatology and bImmunology, John Radcliffe Hospital, Oxford, UK
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
A 43-year-old man with a hyper-immunoglobulin M syndrome due to CD40 ligand deficiency presented with insidious onset of recurrent diarrhoea and deranged liver function tests. Standard stool microscopy was repeatedly negative for cryptosporidia but immunofluorescent testing and polymerase chain reaction demonstrated the presence of infection eventually. Despite both paromomycin and nitazoxanide, he developed sclerosing cholangitis secondary to cryptosporidial infection. Whilst being considered for dual bone marrow and liver transplantation, he was found to have cholangiocarcinoma on imaging after three biopsies of a suspicious lesion. This is a rare complication of this combined immune deficiency predominantly in children that has not been reported previously in a long-term survivor with this condition.
© 2012 S. Karger AG, Basel
Török O, Tóth B, Erdös M, Csorba G, Gyimesi E, Balogh I, Tóth Z, Maródi L: Molecular diagnostic challenges and complex management of consecutive twin pregnancies in a family with CD40 ligand deficiency. Scand J Immunol 2011, E-pub ahead of print.
Notorangelo LD, Toniati P, Vihinen M: European registry for X-linked immunodeficiency with hyper-IgM. Yearly Report, 2000.
- Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, et al: The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 2003;82:373–384.
- Dimicoli S, Bensoussan D, Latger-Cannard V, Straczek J, Antunes L, Mainard L, et al: Complete recovery from Cryptosporidium parvum infection with gastroenteritis and sclerosing cholangitis after successful bone marrow transplantation in two brothers with X-linked hyper-IgM syndrome. Bone Marrow Transplant 2003;32:733–737.
- Erdos M, Garami M, Rákóczi E, Zalatnai A, Steinbach D, Baumann U, Kropshofer G, Tóth B, Maródi L: Neuroendocrine carcinoma associated with X-linked hyper-immunoglobulin M syndrome: report of four cases and review of the literature. Clin Immunol 2008;129:455–461.
- Hayward AR, Levy J, Facchetti F, Notorangelo L, Ochs HD, Etzioni A, et al: Cholangiopathy and tumours of the pancreas, liver and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol 1997;158:977–983.
- McLauchlin J, Amar CF, Pedraza-Diaz S, Mieli-Vergani G, Hadzic N, Davies EG: Polymerase chain reaction-based diagnosis of infection with Cryptosporidium in children with primary immunodeficiencies. Pediatr Infect Dis J 2003;22:329–335.
Lin SC, Shyur SD, Ma YC, Huang LH, Lee HC, Lee WI: Recurrent acalculous cholecystitis and sclerosing cholangitis in a patient with X-linked hyper-immunoglobulin M syndrome. J Formos Med Assoc 2005;104:421–426.
- Bejaoui M, Mellouli F, Chouanine R, Dellagi K, Barbouche MR: The hyper-IgM syndrome: 13 observations. Presse Med 2003;32:544–549.
- Banatvala N, Davies J, Kanariou M, Strobel S, Levinsky R, Morgan G: Hypogammaglobulinaemia associated with normal or increased IgM (the hyper-IgM syndrome): a case series review. Arch Dis Child 1994;71:150–152.
- Notarangelo LD, Duse M, Ugazio AG: Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev 1992;3:101–122.
- Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, et al: Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997;131:47–54.
- Tomizawa D, Imai K, Ito S, Kajiwara M, Minegishi Y, Nagasawa M, et al: Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience. Am J Hematol 2004;76:33–39.
- Khawaja K, Gennery AR, Flood TJ, Abinum M, Cant AJ: Bone marrow transplantation for CD40 ligand deficiency: a single centre experience. Arch Dis Child 2001;84:508–511.
- Duplantier JE, Seyama K, Day NK, Hitchcock R, Nelson RP, Ochs HD, et al: Immunologic reconstitution following bone marrow transplantation for X-linked hyper-IgM syndrome. Clin Immunol 2001;98:313–318.
- Rodrigues F, Davies EG, Harrison P, McLauchlin J, Karani J, Portman B, et al: Liver disease in children with primary immunodeficiencies. J Pediatr 2004;145:333–339.
- Cosyns M, Tsirikin S, Jones M, Flavell R, Kikutani H, Hayward AR: Requirement for CD40-CD40 ligand interaction for elimination of Cryptosporidium parvum from mice. Infect Immun 1998;66:603–607.
- Eichelberger MC, Suresh P, Rehg JE: Protection from Cryptosporidium parvum infection by gamma delta T cells in mice that lack alpha beta T cells. Comp Med 2000;50:270–276.
- Meamar AR, Rezaian M, Rezaie S, Mohraz M, Kia EB, Houpt ER, et al: Cryptosporidium parvum bovine genotype oocysts in the respiratory samples of an AIDS patient: efficacy of treatment with a combination of azithromycin and paromomycin. Parasitol Res 2006;98:593–595.
American Hospital Formulary Service (AHFS) 2002. Bethesda, American Society of Health System Pharmaceuticals, 2002.
Abubakar I, Aliya SH, Arumugam C, Hunter PR, Usman NK: Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev 2007;1:CD004932.
- Gennery AR, Khawaja K, Veys P, Bredius RG, Notarangelo LD, Mazzolari E, et al: Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993–2002. Blood 2004;103:1152–1157.
- Stephens J, Cosyns M, Jones M, Hayward A: Liver and bile duct pathology following Cryptosporidium parvum infection of immunodeficient mice. Hepatology 1999;30:27–35.
- Abdalian R, Heathcote E: J. Sclerosing cholangitis: a focus on secondary causes. Hepatology 2006;44:1063–1074.
- Seyama K, Nonoyama S, Gangsaas I, Hollenbaugh D, Pabst HF, Aruffo A, et al: Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper-IgM syndrome. Blood 1998;92:2421–2434.
- Lee W-I, Torgerson TR, Schumacher MJ, Yel L, Zhu Q, Ochs HD: Molecular analysis of a large cohort of patients with the hyper-IgM syndrome (HIGM). Blood 2005;105:1881–1890.
- Danielian S, Oleastro M, Eva Rivas M, Cantisano C, Zelazko M: Clinical follow-up of 11 Argentinian CD40L-deficient patients with 7 unique mutations including the so-called ‘milder’ mutants. J Clin Immunol 2007;27:455–459.
- de Vries E, Noordzij JG, Davies EG, Hartwig N, Breuning MH, Van Dongen JJM, et al: The 782C->T (T254M) XHIM mutation: lack of a tight phenotype-genotype relationship. Blood 1999;94:1488–1490.
- Thomas C, de Saint Basile G, Le Deist F, Theophile D, Benkerrou M, Haddad E, et al: Brief report: correction of X-linked hyper-IgM syndrome by allogeneic bone marrow transplantation. N Engl J Med 1995;333:426–429.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.